Aventis Pharma S.a.

Roussel Uclaf

Philippe Becourt

Christian Desesquelle

Jean-Luc Dubois

Pierre Metziger

Josiane Chauvin

Robert Georges

Detlev Schwabe

Serge Segot Chicq

The invention concerns a pharmaceutical composition comprises trimegestone optionally associated with an oestrogen, characterized in that it comprises a buffer solution whereof the pH, when it is introduced in the composition, ranging essentially between 2 and 5.5. The invention also concerns the methods for making such a composition and the primary package containing them.

Pharmaceutical compositions comprising trimegestone

The invention relates to a pharmaceutical formulation in the form of a powder which is administered orally in an aqueous suspension, having a masked taste, and comprising at least one cellulose polymer, a methacrylic polymer and an active ingredient which is distributed in a homogeneous manner in a molecular state in an atomized matrix, in addition to an alkaline agent and an adsorbing agent, a method for the production thereof and a method for masking the taste of pharmaceutical products.

Pharmaceutical formulation having a masked taste and method for the production thereof

Pill tablet

A soft capsule containing a) a capsule casing containing gelatin and optionally a plasticizer and other additives, b) a compound of the formula ##STR1## wherein R1, R2 and R3 are individually selected from the group consisting of hydrogen, halogen, alkyl and alkoxy of 1 to 5 carbon atoms, --OH, --CF3, --NO2, --NH2, alkylamino and dialkylamino of 1 to 5 alkyl carbon atoms and acylamino of acyl of an aliphatic carboxylic acid of 1 to 6 carbon atoms or a non-toxic, pharmaceutically acceptable acid addition salt thereof and c) at least one mineral oil and optionally a pharmaceutical carrier.

Soft capsules containing dinreburnamenine compounds

Growing community of inventors

Massy, France

Philippe Becourt